Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
The purpose of this study is to determine the efficacy and tolerance of the association of
 two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and
 Zoladex® 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.
Inclusion Criteria:

 -  Signed informed consent, premenopausal women 18 years or older, histologically or
 cytologically confirmed locally advanced or metastatic breast cancer, suitable for
 endocrine treatment, no curative treatment available,, one or more measurable lesions,
 life expectancy more than 6 months, normal biological parameters.

 Exclusion Criteria:

 -  Presence of life-threatening metastases, previous endocrine therapy or chemotherapy
 for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe
 or uncontrolled systemic disease, pituitary adenoma, High risk of medullar
 compression.